[{"id":"8943f47c-7aa3-4bea-83e0-413753bdafd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06102525","created_at":"2023-10-26T15:14:16.345Z","updated_at":"2024-07-02T16:35:31.481Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma","source_id_and_acronym":"NCT06102525","lead_sponsor":"Rznomics, Inc.","biomarkers":" TERT","pipe":"","alterations":" ","tags":["TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RZ-001 • Valcyte (valganciclovir)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2023-10-26"},{"id":"aff38d03-8427-4efd-9ff1-ec4481379fbb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05595473","created_at":"2022-10-27T15:58:19.813Z","updated_at":"2024-07-02T16:36:01.714Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Hepatocellular Carcinoma","source_id_and_acronym":"NCT05595473","lead_sponsor":"Rznomics, Inc.","biomarkers":" TERT","pipe":"","alterations":" ","tags":["TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RZ-001 • Valcyte (valganciclovir)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/29/2022","start_date":" 07/29/2022","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2022-10-27"},{"id":"9514758f-4829-4ce5-a673-47f4c5801dbd","acronym":"VIGAS2","url":"https://clinicaltrials.gov/study/NCT04116411","created_at":"2021-01-18T20:07:16.086Z","updated_at":"2024-07-02T16:36:24.504Z","phase":"Phase 2","brief_title":"A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients","source_id_and_acronym":"NCT04116411 - VIGAS2","lead_sponsor":"Cecilia Soderberg-Naucler","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Valcyte (valganciclovir)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2021-09-13"},{"id":"3fa4ebd3-233e-4045-a6de-5d818e459482","acronym":"","url":"https://clinicaltrials.gov/study/NCT01441063","created_at":"2021-01-18T05:58:20.977Z","updated_at":"2024-07-02T16:36:39.566Z","phase":"Phase 2","brief_title":"Tocilizumab for KSHV-Associated Multicentric Castleman Disease","source_id_and_acronym":"NCT01441063","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Actemra IV (tocilizumab) • Valcyte (valganciclovir)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 09/13/2011","start_date":" 09/13/2011","primary_txt":" Primary completion: 06/06/2018","primary_completion_date":" 06/06/2018","study_txt":" Completion: 10/05/2020","study_completion_date":" 10/05/2020","last_update_posted":"2020-10-27"},{"id":"5ff22ee6-6c95-4b3e-80e2-eb69bcdf6c52","acronym":"","url":"https://clinicaltrials.gov/study/NCT01199562","created_at":"2021-01-18T04:48:21.624Z","updated_at":"2025-02-25T16:23:31.204Z","phase":"","brief_title":"Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant","source_id_and_acronym":"NCT01199562","lead_sponsor":"City of Hope Medical Center","biomarkers":" NCAM1 • LAMP2","pipe":"","alterations":" ","tags":["NCAM1 • LAMP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Valcyte (valganciclovir)"],"overall_status":"Completed","enrollment":" Enrollment 153","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 12/01/2013","primary_completion_date":" 12/01/2013","study_txt":" Completion: 12/01/2013","study_completion_date":" 12/01/2013","last_update_posted":"2019-04-25"}]